These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31862137)

  • 1. [Evolution of the costs and management of lung cancer between 2004 and 2014].
    Gadby F; Descourt R; Robinet G; Quere G; Gouva S; Roge C; Couturaud F; Chouaid C
    Rev Mal Respir; 2020 Jan; 37(1):1-7. PubMed ID: 31862137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
    Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and costs of treating lung cancer patients in a university hospital.
    Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA
    Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations in lung cancer over multiple decades: an analysis of outcomes and cost at a single high-volume institution.
    Lanuti M; Hong HJ; Ali S; Stock C; Temel J; Mathisen D; Michaelson JS
    Eur J Cardiothorac Surg; 2014 Aug; 46(2):254-61; discussion 261. PubMed ID: 24453265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.
    Park YS; Kim SH; Park SK; Park BJ; Kim YT; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Shim YS; Yang SC
    Lung Cancer; 2010 May; 68(2):299-304. PubMed ID: 19646776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
    Giuliani J; Marzola M
    Cutan Ocul Toxicol; 2013 Sep; 32(3):248-51. PubMed ID: 23368942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The cost components of the management strategies for lung cancer in France].
    Vergnenègre A; Molinier L; Combescure C; Daurès JP; Housset B; Chouaid C
    Rev Mal Respir; 2004 Jun; 21(3 Pt 1):501-10. PubMed ID: 15292842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economics of lung cancer management in Canada.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM; Brooks JM; Kim J
    Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer among native and foreign-born Swedes: histopathology, treatment, and survival.
    Koyi H; Hillerdal G; Andersson O; Högberg H; Brandén E
    Acta Oncol; 2016 Nov; 55(11):1344-1348. PubMed ID: 27556916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Hospice Care on Survival and Healthcare Costs for Patients with Lung Cancer: A National Longitudinal Population-Based Study in Taiwan.
    Chiang JK; Kao YH; Lai NS
    PLoS One; 2015; 10(9):e0138773. PubMed ID: 26406871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
    Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
    BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China.
    Zhou LF; Zhang MX; Kong LQ; Lyman GH; Wang K; Lu W; Feng QM; Wei B; Zhao LP
    Cancer Invest; 2017 May; 35(5):345-357. PubMed ID: 28368669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting hospital costs in lung cancer patients in the United Kingdom.
    Kennedy MP; Hall PS; Callister ME
    Lung Cancer; 2016 Jul; 97():8-14. PubMed ID: 27237021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An economic analysis of the management of bone metastases in lung cancer].
    Decroisette C; Locher C; Iglesias E; Chouaid C;
    Rev Mal Respir; 2006 Nov; 23(5 Pt 1):497-502. PubMed ID: 17314755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact on health service costs of medical technologies used in management of prostatic cancer.
    Holmberg H; Carlsson P; Kalman D; Varenhorst E
    Scand J Urol Nephrol; 1998 May; 32(3):195-9. PubMed ID: 9689698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
    Levy-Piedbois C; Durand-Zaleski I; Juhel H; Schmitt C; Bellanger A; Piedbois P
    Ann Oncol; 2000 Feb; 11(2):157-61. PubMed ID: 10761749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
    Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
    Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.